In an effort to maintain journalistic accuracy I wanted to add a few comments to my article published yesterday based on new information: 1. The acquisition talks between SJM and Abbott Laboratories did not begin until December 2015, not 2014/mid 2015 as I initially reported. This is reported to be documented in an SEC filing. The sale of the company was announced in April 2016. 2. In an effort to provide more clarity on the price/value of SJM, The stock deal at the time of the acquisition was announced at a price of $85 a share. The price in 2014 was roughly $81 a share and in December 2015 the price was $61 a share. 3. In the interest of full disclosure, I have received consulting fees from all of the mentioned manufacturers including Medtronic, St Jude Medical, Biotronik and Boston Scientific in the past 10 years.